AngioDynamics ANGO United States — Net Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AngioDynamics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: AngioDynamics’s 10-Q, filed April 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about AngioDynamics's united states — net sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AngioDynamics's united states — net sales?
- AngioDynamics (ANGO) reported united states — net sales of $67.28M in Q4 2025.
- How has AngioDynamics's united states — net sales changed year-over-year?
- AngioDynamics's united states — net sales increased by 9.7% year-over-year, from $61.34M to $67.28M.
- What is the long-term trend for AngioDynamics's united states — net sales?
- Over 4 years (2021 to 2025), AngioDynamics's united states — net sales has grown at a 1.4% compound annual growth rate (CAGR), from $237.04M to $250.98M.
- What does united states — net sales mean?
- This metric represents the total revenue generated from the sale of medical devices and therapeutic solutions within the domestic market. It serves as a primary indicator of the company's market penetration and commercial performance in its largest geographic region. Tracking this figure helps investors assess the stability and growth trajectory of the core business operations in the United States.